FSSAI Orders Removal of ‘ORS’ from Food and Beverage Labels

New Delhi– The Food Safety and Standards Authority of India (FSSAI) has directed all food and beverage manufacturers to immediately remove the term “ORS” (Oral Rehydration Solution) from product labels, citing misleading claims about health benefits.

The order aims to prevent consumer confusion, as only medically certified ORS products can use the term. Non-compliance will attract fines up to ₹10 lakh. Manufacturers have 30 days to update packaging. FSSAI emphasized stricter enforcement to protect public health.

Background: Public Interest Litigation

The regulatory intervention follows a nearly decade-long campaign by Hyderabad-based paediatrician Dr. Sivaranjani Santosh against sugar-rich beverages falsely marketed as ORS. In 2022, she filed a Public Interest Litigation (PIL) in the Telangana High Court challenging beverages that claimed to be ORS but failed to meet WHO-recommended electrolyte and glucose standards.

Her petition highlighted the potential health risks, especially to children and diabetic patients, and her complaints reached the Ministry of Health and Family Welfare, prompting regulatory scrutiny.

Court and Regulatory Actions

The Telangana High Court directed FSSAI and the Drug Controller General of India to respond, recognising the public health implications of misleading ORS claims.

In April 2022, FSSAI issued its first restriction, but in July the regulator temporarily allowed companies holding valid trademarks to continue production until the Controller General of Patents, Designs and Trademarks issued a final decision.

Health Risks from Mislabelled Beverages

WHO-approved ORS has a total osmolarity of 245 mOsm/L, with precise quantities of sodium, potassium, chloride, and dextrose. In contrast, many marketed products contained up to 120 grams of sugar per litre, with minimal electrolytes, posing serious health risks.

Related Posts

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

The report emphasizes that absolute R&D spending remains modest and identifies expanding investment in advanced biologics and AI-driven drug discovery as the “largest opportunity” for bridging the innovation divide. Recent…

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

Early-stage activity drove the month, accounting for 73.6 per cent of total investments, while seed-stage rounds contributed the remaining 26.4 per cent. India’s pharma and healthcare funding for November 2025…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

Novo Nordisk gears up for December Ozempic launch

Novo Nordisk gears up for December Ozempic launch

Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit

Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit